{"nctId":"NCT01132118","briefTitle":"Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis","startDateStruct":{"date":"2010-06"},"conditions":["Rheumatoid Arthritis","Insulin Resistance"],"count":30,"armGroups":[{"label":"Placebo then HCQ","type":"OTHER","interventionNames":["Drug: Hydroxychloroquine"]},{"label":"HCQ then Placebo","type":"OTHER","interventionNames":["Drug: Hydroxychloroquine"]}],"interventions":[{"name":"Hydroxychloroquine","otherNames":["Plaquenil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 or older\n* Able to provide informed consent and comply with study visits\n* Hemoglobin ≥ 10 g/dL (within last two months)\n* WBC ≥ 4 K/uL (within last two months)\n* Platelet count ≥ 150 ≤ 450 K/uL (within last two months)\n* (GFR) Creatinine clearance ≥ 70 ml/min (MDRD) (within last two months)\n* SGOT, SGPT ≤ 1.5 times upper limits of normal (within last two months)\n* Normal eye exam within 12 months of study entry (copy of letter from subject's ophthalmologist or optometrist stating that the subject has no evidence of macular pathology)\n* Diagnosis of rheumatoid arthritis\n\nExclusion Criteria:\n\n* History of any neuromuscular disease including muscular dystrophy, metabolic myopathies, peripheral neuropathy, multiple sclerosis, and other myopathies or myositides\n* History of diabetes or fasting plasma glucose of 126 mg/dl or greater\n* History of any untoward reaction to antimalarials\n* Uncontrolled hypertension (\\>140/90)\n* History of any ophthalmologic disease except for glaucoma or cataracts\n* Planned elective surgery during the study period\n* Digoxin therapy\n* Treatment with corticosteroids (\\> 5 mg) for any disorder\n* History of psoriasis\n* Any chronic disease that in the opinion of the investigator warrants exclusion (e.g. inflammatory bowel disease, malignancy other than basal cell carcinoma, chronic liver disease)\n* History of chronic intestinal disorders (Crohn's disease, ulcerative colitis, celiac sprue, collagenous colitis, eosinophilic enteritis)\n* Creatinine clearance ≤ 60 ml/min (MDRD) (within last two months)\n* Hemoglobin ≤ 10 g/dL (within last two months)\n* WBC ≤ 4 K/uL (within last two months)\n* Platelet count ≤ 150 ≥ 450 K/uL (within last two months)\n* SGOT, SGPT ≥ 1.5 times upper limits of normal (within last two months)\n* Women who are pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Insulin Sensitivity Index","description":"We will examine the effect of HCQ on the Matsuda Insulin Sensitivity Index (ISI) during the active treatment phase compared with placebo phase.\n\nISI is based on insulin and glucose levels in a fasting state during an oral glucose tolerance test (OGTT) and is calculated as follows:\n\nISI (Matsuda) = 10000/√ G0 X I0 X Gmean X Imean\n\nG0 - fasting plasma glucose (mg/dL) I0 - fasting plasma insulin (mIU/L) Gmean - mean plasma glucose during OGTT (mg/dL) Imean - mean plasma insulin during OGTT (mIU/L)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"4.8"},{"groupId":"OG001","value":"7.7","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"4.5"},{"groupId":"OG001","value":"7.8","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.9"},{"groupId":"OG001","value":"0.14","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"HOMA-IR","description":"We will examine the effect of HCQ on HOMA-IR during the active treatment phase compared with placebo phase.\n\nHOMA-IR = (Glucose x insulin)/405","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.7"},{"groupId":"OG001","value":"2.0","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.0"},{"groupId":"OG001","value":"1.6","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.5"},{"groupId":"OG001","value":"-0.42","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"HOMA-B","description":"HOMA-B = (360 x Insulin)/(Glucose - 63)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116.5","spread":"100.4"},{"groupId":"OG001","value":"116.5","spread":"100.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.8","spread":"81.6"},{"groupId":"OG001","value":"109.7","spread":"82.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"72.9"},{"groupId":"OG001","value":"-6.8","spread":"78.0"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol","description":"mg/dL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192.4","spread":"37.5"},{"groupId":"OG001","value":"192.4","spread":"37.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179.7","spread":"44.3"},{"groupId":"OG001","value":"189.4","spread":"37.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.7","spread":"20.0"},{"groupId":"OG001","value":"-3.0","spread":"22.4"}]}]}]},{"type":"SECONDARY","title":"LDL Cholesterol","description":"mg/dL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114.1","spread":"29.8"},{"groupId":"OG001","value":"114.1","spread":"29.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.7","spread":"36.7"},{"groupId":"OG001","value":"109.9","spread":"33.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":"20.1"},{"groupId":"OG001","value":"-4.2","spread":"17.7"}]}]}]},{"type":"SECONDARY","title":"HDL Cholesterol","description":"mg/dL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":"17.9"},{"groupId":"OG001","value":"58.1","spread":"17.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":"18.2"},{"groupId":"OG001","value":"60.3","spread":"17.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"6.7"},{"groupId":"OG001","value":"2.2","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"Triglycerides","description":"mg/dL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.6","spread":"44.0"},{"groupId":"OG001","value":"100.6","spread":"44.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":"41.7"},{"groupId":"OG001","value":"95.6","spread":"44.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"45.0"},{"groupId":"OG001","value":"-5.0","spread":"20.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Rash","Liver Function Test Abnormality"]}}}